What's Happening?
Kernal Biologics, a TechBio company, is set to showcase its mRNA 2.0 platform and T-cell-targeted lipid nanoparticles (tLNPs) for in situ CAR T programming at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The presentations will
highlight the company's approach to selectively transduce resting T cells in vivo, using machine-learning-designed mRNA payloads. This technology aims to enhance the safety and scalability of CAR T therapies by ensuring therapeutic payloads are active only within target cells.
Why It's Important?
The development of in situ CAR T programming represents a significant advancement in cell therapy, potentially overcoming logistical and toxicological barriers associated with traditional CAR T treatments. By enabling targeted delivery and selective translation of mRNA, Kernal Biologics' platform could make CAR T therapies more accessible and safer for a broader range of patients. This innovation could transform the field of cell therapy, offering new treatment options for autoimmune diseases and blood cancers, and highlighting the growing role of AI and machine learning in advancing medical research.
